01 1Betanis/Myrbetriq/Beiga
02 7Betanis/Myrbetriq/Betmiga
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 1,492
2019 Revenue in Millions : 1,451
Growth (%) : 3
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 1,420
2020 Revenue in Millions : 1,481
Growth (%) : 3
Main Therapeutic Indication : Nephrology
Currency : USD
2022 Revenue in Millions : 1,437
2021 Revenue in Millions : 1,455
Growth (%) : -1
Main Therapeutic Indication : Nephrology
Currency : USD
2023 Revenue in Millions : 1,284
2022 Revenue in Millions : 1,437
Growth (%) : 1
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 1,287
2017 Revenue in Millions : 1,003
Growth (%) : 28%
Main Therapeutic Indication : Renal Disorders
Currency : USD
2016 Revenue in Millions : 839
2015 Revenue in Millions : 679
Growth (%) : 24
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 1,472
2018 Revenue in Millions : 1,325
Growth (%) : 11
Main Therapeutic Indication : Renal Disorders
Currency : USD
2017 Revenue in Millions : 1,070
2016 Revenue in Millions : 895
Growth (%) : 20
LOOKING FOR A SUPPLIER?
